Ingalfarma’s Merger with Level Bioscience

Carey and Andes IP advised on the deal

Ingalfarma finalized the merger agreement with Level Bioscience.

Based in Chile, Ingalfarma is a biomedical company that develops innovative treatments aimed at solving complex oral pathologies.

Level Bioscience engages in research on opportunity offerted by the use of statin for oral health .

Carey advised Ingalfarma with Francisco Guzmán (Picture) and Nicolás Calderón.

Andes IP advised Level Bioscience with Andrea Lobos, Felipe Burgos Osorio and Rodrigo Sammut Linares.

Involved fees earner: Andrea Lobos Cáceres – Andes IP; Felipe Burgos Osorio – Andes IP; Rodrigo Sammut – Andes IP; Francisco Guzmán – Carey; Nicolás Calderón – Carey;

Law Firms: Andes IP; Carey;

Clients: Ingalfarma; Level Bioscience;


Author: Ambrogio Visconti.